Total Payments
$5,716
2024 Payments
$821.93
Companies
51
Transactions
329
Medicare Patients
4,012
Medicare Billing
$522,089
Payment Breakdown by Category
Food & Beverage$5,239 (91.7%)
Education$476.84 (8.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,239 | 319 | 91.7% |
| Education | $476.84 | 10 | 8.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $723.63 | 38 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $664.88 | 41 | $0 (2024) |
| Amgen Inc. | $445.84 | 23 | $0 (2022) |
| Genentech USA, Inc. | $403.38 | 32 | $0 (2024) |
| Incyte Corporation | $391.67 | 19 | $0 (2024) |
| PFIZER INC. | $308.56 | 23 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $260.05 | 5 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $170.20 | 11 | $0 (2018) |
| Celgene Corporation | $167.86 | 11 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $142.08 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $821.93 | 37 | Janssen Biotech, Inc. ($174.30) |
| 2023 | $566.34 | 30 | Novartis Pharmaceuticals Corporation ($80.63) |
| 2022 | $627.47 | 33 | Amgen Inc. ($91.82) |
| 2021 | $68.99 | 4 | SUN PHARMACEUTICAL INDUSTRIES INC. ($21.62) |
| 2020 | $374.13 | 21 | Exelixis Inc. ($63.28) |
| 2019 | $520.68 | 32 | Amgen Inc. ($111.16) |
| 2018 | $1,536 | 83 | Novartis Pharmaceuticals Corporation ($253.49) |
| 2017 | $1,200 | 89 | Novartis Pharmaceuticals Corporation ($206.22) |
All Payment Transactions
329 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $28.02 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: Oncology | ||||||
| 11/27/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $25.20 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.69 | General |
| Category: Hematology/Oncology | ||||||
| 10/31/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: Oncology | ||||||
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: Oncology | ||||||
| 10/03/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $27.03 | General |
| Category: Oncology | ||||||
| 10/02/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $28.05 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2024 | GENZYME CORPORATION | ENJAYMO (Biological), CABLIVI | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: Hematology | ||||||
| 09/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $34.29 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: Oncology | ||||||
| 08/27/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $15.88 | General |
| 08/21/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $30.30 | General |
| Category: Oncology | ||||||
| 07/31/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: ONCOLOGY | ||||||
| 07/24/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: Oncology | ||||||
| 07/17/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Food and Beverage | In-kind items and services | $31.67 | General |
| Category: BioOncology | ||||||
| 07/15/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 06/14/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $17.59 | General |
| Category: Hematology/Oncology | ||||||
| 05/31/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $20.05 | General |
| Category: Oncology | ||||||
| 05/14/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $22.17 | General |
| 05/09/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $22.68 | General |
| Category: Oncology | ||||||
| 05/01/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $6.86 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 1,016 | 1,905 | $400,032 | $162,644 |
| 2022 | 7 | 1,172 | 2,085 | $304,807 | $123,851 |
| 2021 | 8 | 1,103 | 1,828 | $290,757 | $121,563 |
| 2020 | 6 | 721 | 1,484 | $301,105 | $114,030 |
Total Patients
4,012
Total Services
7,302
Medicare Billing
$522,089
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 530 | 1,324 | $295,252 | $121,796 | 41.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 168 | 168 | $71,568 | $26,605 | 37.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 66 | 73 | $20,805 | $7,815 | 37.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 201 | 288 | $2,592 | $2,412 | 93.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 13 | $3,887 | $1,749 | 45.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 16 | 16 | $2,432 | $1,158 | 47.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 23 | $3,496 | $1,109 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 270 | 650 | $143,854 | $62,303 | 43.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 343 | 493 | $74,114 | $29,129 | 39.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 66 | 66 | $28,021 | $11,499 | 41.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 94 | 94 | $31,634 | $10,831 | 34.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 53 | 64 | $18,240 | $7,021 | 38.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 334 | 701 | $6,309 | $2,077 | 32.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 17 | $2,635 | $991.11 | 37.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 228 | 540 | $118,260 | $51,161 | 43.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 352 | 549 | $81,801 | $35,842 | 43.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 92 | 92 | $30,820 | $11,721 | 38.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 75 | 81 | $22,956 | $8,635 | 37.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 47 | 47 | $19,787 | $7,684 | 38.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 30 | 31 | $9,145 | $3,656 | 40.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 25 | $3,821 | $1,484 | 38.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 260 | 463 | $4,167 | $1,380 | 33.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 193 | 643 | $139,307 | $53,879 | 38.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 341 | 637 | $93,713 | $33,407 | 35.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 97 | 97 | $40,837 | $15,905 | 38.9% |
About Dr. Syed Arshad, MD
Dr. Syed Arshad, MD is a Hematology & Oncology healthcare provider based in Maryville, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1154396182.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Syed Arshad, MD has received a total of $5,716 in payments from pharmaceutical and medical device companies, with $821.93 received in 2024. These payments were reported across 329 transactions from 51 companies. The most common payment nature is "Food and Beverage" ($5,239).
As a Medicare-enrolled provider, Arshad has provided services to 4,012 Medicare beneficiaries, totaling 7,302 services with total Medicare billing of $522,089. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Maryville, IL
- Active Since 02/22/2006
- Last Updated 08/19/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1154396182
Products in Payments
- IMBRUVICA (Drug) $401.04
- JAKAFI (Drug) $254.30
- SOLIRIS (Drug) $217.78
- AFINITOR (Drug) $183.12
- DARZALEX (Biological) $181.69
- Neulasta (Biological) $148.72
- JADENU (Drug) $138.02
- TECENTRIQ (Biological) $133.61
- Avastin (Biological) $125.12
- Erleada (Drug) $112.69
- Lenvima (Drug) $106.62
- OPDIVO (Biological) $103.69
- TASIGNA (Drug) $99.93
- PROMACTA (Drug) $87.58
- BOSULIF (Drug) $82.71
- GILOTRIF (Drug) $80.46
- Cabometyx (Drug) $76.72
- Enhertu (Drug) $71.06
- MONJUVI (Drug) $69.49
- RYBREVANT (Drug) $68.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.